BBIO
BridgeBio Pharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$13.54B
P/E Ratio
—
EPS
$-3.74
Beta
1.02
52W High
$84.94
52W Low
$31.77
50-Day MA
$71.23
200-Day MA
$65.98
Dividend Yield
—
Profit Margin
-124.40%
Forward P/E
—
PEG Ratio
—
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Fundamentals
| Revenue (TTM) | $579.96M |
| Gross Profit (TTM) | $551.70M |
| EBITDA | $-498.88M |
| Operating Margin | -54.50% |
| Return on Equity | -1790.00% |
| Return on Assets | -28.00% |
| Revenue/Share (TTM) | $3.01 |
| Book Value | $-10.71 |
| Price-to-Book | 123.68 |
| Price-to-Sales (TTM) | 23.34 |
| EV/Revenue | 26.02 |
| EV/EBITDA | -9.40 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 66.80% |
| Shares Outstanding | $195.86M |
| Float | $162.93M |
| % Insiders | 3.92% |
| % Institutions | 102.56% |
Historical Volatility
HV 10-Day
50.24%
HV 20-Day
45.38%
HV 30-Day
41.66%
HV 60-Day
47.96%
HV Rank
49.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($101.89 target)
6
Strong Buy16
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026